Report - ADA 2018 outline - Novo Nordisk · ADA 2018 investor presentation 59% 72% 80% 34% 0% 20% 40% 60% 80% 100% Oral sema 3 mg Oral Sema 7 mg Oral sema 14 mg Placebo Proportion of patients

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form